Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
[HTML][HTML] Pediatric acute lymphoblastic leukemia
H Inaba, CG Mullighan - Haematologica, 2020 - ncbi.nlm.nih.gov
The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …
Blinatumomab added to chemotherapy in infant lymphoblastic leukemia
IM van der Sluis, P de Lorenzo… - … England Journal of …, 2023 - Mass Medical Soc
Background KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an
aggressive disease with 3-year event-free survival below 40%. Most relapses occur during …
aggressive disease with 3-year event-free survival below 40%. Most relapses occur during …
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
S Gupta, RE Rau, JA Kairalla, KR Rabin… - … England Journal of …, 2024 - Mass Medical Soc
Background B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood
cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of …
cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of …
Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
N Toft, H Birgens, J Abrahamsson, L Griškevičius… - Leukemia, 2018 - nature.com
Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …
Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16
S Jeha, D Pei, J Choi, C Cheng… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Despite contemporary treatment, up to 10% of children with acute lymphoblastic
leukemia still experience relapse. We evaluated whether a higher dosage of PEG …
leukemia still experience relapse. We evaluated whether a higher dosage of PEG …
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
DT Teachey, CH Pui - The Lancet Oncology, 2019 - thelancet.com
Contemporary paediatric clinical trials have improved 5-year event-free survival above 85%
and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in …
and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in …
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease–directed therapy
S Jeha, J Choi, KG Roberts, D Pei, E Coustan-Smith… - Blood cancer …, 2021 - AACR
We evaluated clinical significance of recently identified subtypes of acute lymphoblastic
leukemia (ALL) in 598 children treated with minimal residual disease (MRD)–directed …
leukemia (ALL) in 598 children treated with minimal residual disease (MRD)–directed …
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
NJ Short, H Kantarjian, F Ravandi… - Blood …, 2022 - ashpublications.org
Measurable residual disease (MRD) is highly prognostic for relapse and overall survival
(OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent “MRD …
(OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent “MRD …
Precision medicine in acute lymphoblastic leukemia
CH Pui - Frontiers of medicine, 2020 - Springer
The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …